Data / Drug companies / BeOne Medicines USA, Inc.
BeOne Medicines USA, Inc.: 11 products in the FDA NDC directory, labeler code 72579
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
BeOne Medicines USA, Inc. (labeler code 72579) lists 11 products in the FDA National Drug Code Directory, covering 3 finished drugs by generic name. By type: 9 prescription drugs, 2 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on September 14, 2026.
The request: Watch BeOne Medicines USA, Inc. (FDA labeler code 72579): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72579
- Products in commercial distribution
- 11
- Packages
- 31
- Finished drugs by generic name
- 3
- Prescription products
- 9
- Over the counter products
- 0
- Started marketing in the last 12 months
- 8
- Earliest marketing start
- November 14, 2019
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 7 | 63.6% |
| Biologics (BLA) | 2 | 18.2% |
| Drugs for further processing | 2 | 18.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 9 | 81.8% |
| Drugs for further processing | 2 | 18.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Sonrotoclax | 5 | 1 |
| Zanubrutinib | 2 | 1 |
| Tislelizumab-jsgr | 2 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 7 | 63.6% |
| Injection, solution, concentrate | 2 | 18.2% |
| Kit | 1 | 9.1% |
| Capsule | 1 | 9.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Zanubrutinib | 72579-901 | Tablet, film coated | Drugs for further processing | September 14, 2026 |
| Sonrotoclax | 72579-999 | Tablet, film coated | Drugs for further processing | September 11, 2026 |
| Beqalzi | 72579-025 | Tablet, film coated | New drug applications (NDA) | August 31, 2026 |
| Beqalzi | 72579-022 | Tablet, film coated | New drug applications (NDA) | August 31, 2026 |
| Beqalzi | 72579-020 | Tablet, film coated | New drug applications (NDA) | August 31, 2026 |
| Beqalzi | 72579-017 | Tablet, film coated | New drug applications (NDA) | August 31, 2026 |
| Beqalzi | 72579-015 | Kit | New drug applications (NDA) | August 31, 2026 |
| Tevimbra | 72579-125 | Injection, solution, concentrate | Biologics (BLA) | July 13, 2026 |
| Brukinsa | 72579-122 | Tablet, film coated | New drug applications (NDA) | August 18, 2025 |
| Tevimbra | 72579-121 | Injection, solution, concentrate | Biologics (BLA) | March 14, 2024 |
| Brukinsa | 72579-011 | Capsule | New drug applications (NDA) | November 14, 2019 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.